Schoenfeld Jonathan D, Dranoff Glenn
Harvard Radiation Oncology Program and Harvard Medical School, Boston, MA, USA.
Hum Vaccin. 2011 Sep;7(9):976-81. doi: 10.4161/hv.7.9.16407. Epub 2011 Sep 1.
Tumors stimulate angiogenesis to meet increasing nutrient and oxygen demands. In addition to their role in vascular remodeling, pro-angiogenic cytokines and effector cells contribute to an immune-inhibitory environment associated with advanced malignancies. Despite the critical role of angiogenesis in tumor growth and dissemination, most anti-angiogenic cancer therapies have had only limited success selectively targeting one of the many factors implicated in this process. Similarly, the effectiveness of tumor immunotherapies has been limited by tumor-mediated escape mechanisms and immune suppression. By combining the two strategies, however, anti-angiogenic immunotherapy offers the possibility to more robustly inhibit tumor angiogenesis and simultaneously impact the immune-inhibitory effects of the pro-angiogenic tumor milieu. These potential synergies make the combination of immunotherapy and anti-angiogenic treatment a promising avenue for future research.
肿瘤刺激血管生成以满足不断增加的营养和氧气需求。促血管生成细胞因子和效应细胞除了在血管重塑中发挥作用外，还促成了与晚期恶性肿瘤相关的免疫抑制环境。尽管血管生成在肿瘤生长和扩散中起关键作用，但大多数抗血管生成癌症疗法仅选择性地靶向这一过程中涉及的众多因素之一，取得的成功有限。同样，肿瘤免疫疗法的有效性也受到肿瘤介导的逃逸机制和免疫抑制的限制。然而，通过将这两种策略相结合，抗血管生成免疫疗法有可能更有力地抑制肿瘤血管生成，同时影响促血管生成肿瘤微环境的免疫抑制作用。这些潜在的协同作用使免疫疗法和抗血管生成治疗的联合成为未来研究的一个有前景的途径。
